figshare
Browse
13058_2016_691_MOESM1_ESM.doc (136.5 kB)

Additional file 1: Table S1. of Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Download (136.5 kB)
journal contribution
posted on 2016-03-15, 05:00 authored by Ian Krop, Shanu Modi, Patricia LoRusso, Mark Pegram, Ellie Guardino, Betsy Althaus, Dan Lu, Alexander Strasak, Anthony Elias
Dose-limiting toxicity criteria. (DOC 136 kb)

Funding

Genentech, Inc.

History

Usage metrics

    Breast Cancer Research

    Categories

    Keywords

    AdditionalpertuzumabPhaseHER 2-positive metastatic breast cancer Dose-limiting toxicity criteriaDOC 136 kbtrastuzumab emtansinepaclitaxelT-DM1.

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC